-
Nona Biosciences Partners with Invetx for Animal Health Therapies
•
Nona Biosciences (HKG: 2142), a wholly-owned subsidiary of HBM Holdings Ltd, has announced a partnership with US-based animal health company Invetx, Inc. Under the agreement, Invetx will utilize Nona’s HCAb Harbour Mice platform to develop next-generation biological therapies for animal health. Financial details of the partnership were not disclosed. Significance…
-
AbbVie Reports Strong Q4 and Full-Year 2024 Financials
•
US-based pharmaceutical giant AbbVie (NYSE: ABBV) has released its Q4 and full-year 2024 financial results, recording global net revenues of $15.102 billion (+5.6%) and $56.334 billion (+3.7%) respectively. Within these figures, the US market contributed $11.734 billion (+5.6%) and $43.029 billion (+2.7%) in net revenues during the fourth quarter and…
-
IASO Bio’s CAR-T Therapy Fucaso Accepted for Review in Singapore
•
China-based IASO Biotherapeutics has announced that a New Drug Application (NDA) for its BCMA-targeted chimeric antigen receptor (CAR) T cell therapy Fucaso (equecabtagene autoleucel) has been accepted for review by the Health Sciences Authority (HSA) of Singapore. The therapy is intended for the treatment of relapsed/refractory multiple myeloma (R/R MM)…
-
Novartis Reports 12% YOY Growth in Full-Year Net Sales
•
Swiss pharmaceutical major Novartis (NYSE: NVS) has released its Q4 and full-year 2024 financial report, showing a 12% year-on-year (YOY) expansion in constant currency terms. The company achieved net sales of $50.317 billion, with core operating profit up 22% to $19.494 billion. During the fourth quarter, net sales increased by…
-
Takeda Reports 4.5% Revenue Growth in First Nine Months of Fiscal Year
•
Japan-headquartered Takeda (NYSE: TAK, TYO: 4502) has released its financial results for the 9-month period ended December 31, 2024. The company reported revenues of JPY 3.53 trillion ($22.4 billion), representing a 4.5% growth at constant exchange rates (CER). Sales jumped 14.6% year-on-year (YOY) due to the growth period and continuous…
-
Daiichi Sankyo Reports 16.6% Revenue Growth in First Three Quarters of FY2024
•
Japan-based Daiichi Sankyo (TYO: 4568) has reported revenues of JPY 1.37 trillion ($8.927 billion) for the first three quarters of the fiscal year 2024 (April 1, 2024, to March 31, 2025), representing a 16.6% year-on-year (YOY) growth. Core operating revenue stood at JPY 248.311 billion ($1.621 billion), up 27.6% YOY.…
-
Pfizer Reports 7% Revenue Growth in 2024, Expects Steady Performance in 2025
•
US major Pfizer Inc. (NYSE: PFE) has released its financial results for the fourth quarter and full year of 2024. The company recorded revenues of $63.627 billion for the full year, up 7% year-on-year (YOY) in constant currency terms. Excluding COVID-19 products Paxlovid and Comirnaty, revenues grew by 12%. During…
-
Roche Reports 7% Growth in Full-Year Sales, Strength in Pharmaceuticals
•
Swiss pharmaceutical giant Roche (SWX: ROG) released its Q4 and full-year 2024 financials, reporting a strong year with 7% year-on-year (YOY) growth across the group at constant exchange rates. Total sales reached CHF 60.495 billion ($66.34 billion), while overall group revenues were CHF 62.395 billion ($68.42 billion), also up 7%.…
-
Sanofi Reports Strong Q4 Growth, Plans EUR 5 Billion Share Buyback
•
French pharmaceutical giant Sanofi (NASDAQ: SNY) reported a strong fourth-quarter performance with 10.3% year-on-year (YOY) growth in net sales in constant currency terms, reaching EUR 10.564 billion ($11 billion). The growth was driven by a 56.5% increase in new pharma launches, a 16% rise in sales of Dupixent (dupilumab), and…
-
Xtalpi Partners with JW Pharmaceutical to Enhance Drug Discovery with AI
•
Shenzhen-based QuantumPharm Inc. (HKG: 2228), better known as Xtalpi Inc., a global leader in AI-powered drug discovery, has announced a multi-million RMB strategic partnership with South Korea’s leading pharmaceutical company, JW Pharmaceutical (KRX: 001060). The collaboration aims to integrate AI and automation into drug discovery, enhancing JW Pharmaceutical’s development efficiency,…
-
DeepSeek’s AI: Transforming Drug Development and Healthcare in China
•
DeepSeek, a Chinese artificial intelligence company, is poised to make a significant impact on the pharmaceutical industry through its advanced natural language processing (NLP) and large language model (LLM) technologies. The potential applications span multiple dimensions, including data-driven research, clinical decision-making, and resource management. This analysis explores the potential impacts…
-
MediLink Therapeutics’ YL217 Receives FDA IND Clearance for Novel ADC Targeting Gastrointestinal Cancers
•
MediLink Therapeutics, a clinical-stage biotech company, announced today that its internally developed antibody-drug conjugate (ADC), YL217, has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA). YL217 is the 11th ADC candidate to enter clinical development based on MediLink’s proprietary TMALIN® platform. YL217: A Novel…
-
AbbVie’s 2024 Revenue Grows Despite Humira Decline, Skyrizi and Rinvoq Surge
•
US-based pharmaceutical giant AbbVie (NYSE: ABBV) reported its 2024 financial results on January 31, with total revenue reaching $56.33 billion, a 3.7% increase from the previous year. The company’s R&D investment surged 66.7% to $12.79 billion, reflecting a strategic focus on innovation and new product development. Business Segment PerformanceIn 2024,…
-
PegBio’s Lead Product PB-119 Clears HKEX Hearing for Type 2 Diabetes and Obesity Treatment
•
On January 28, 2025, the Hong Kong Stock Exchange (HKEX) website showed that PegBio Co., Ltd., a Suzhou-based specialist in endocrine metabolism, has successfully passed the HKEX hearing. China International Capital Corporation (CICC) acted as the sole sponsor. Company OverviewPegBio was established in 2008 as a biotechnology company focused on…
-
Roche Reports 7% Revenue Growth in 2024, Driven by Oncology and Ophthalmology
•
Roche (SWX: ROG) released its 2024 annual financial report on January 30, showing a 7% year-on-year increase in revenue to CHF 60.495 billion (USD 68.892 billion), calculated based on the average exchange rate of 2024 (1 CHF = USD 1.1388). The company’s R&D expenditure reached CHF 13.042 billion (USD 14.852…
-
DeepSeek Enhances Biopharma IND and NDA Processes with AI
•
In the regulatory submissions for Investigational New Drug (IND) and New Drug Application (NDA) in the biopharmaceutical sector, DeepSeek, as an AI technology tool or service platform, can enhance the efficiency and compliance of the application process through the following means: Data Management and Analysis Document Automation and Compliance Support…
-
Enhertu Approved by FDA for HR-Positive, HER2-Low Breast Cancer
•
Daiichi Sankyo (TYO: 4568) and AstraZeneca (AZ, NASDAQ: AZN) jointly announced that their co-developed antibody-drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) has received FDA approval for the treatment of unresectable or metastatic hormone receptor (HR) positive, HER2-low (IHC 1+ or IHC 2+/ISH-) or HER2 ultra-low (IHC 0 with membrane staining) breast…
-
Vigonvita Life Sciences Targets HKEX IPO with Integrated Biopharma Model
•
On January 27, 2025, the Hong Kong Stock Exchange (HKEX) website displayed that Suzhou Vigonvita Life Sciences Co., Ltd submitted an application for listing on the HKEX, with CITIC Securities as the sponsor. Company Overview and MissionThe prospectus shows that Vigonvita Bio, established in 2013, is an integrated biopharmaceutical company…
-
CStone Pharmaceuticals Partners with SteinCares for Sugemalimab Commercialization in Latin America
•
CStone Pharmaceuticals (HKG: 2616), a China – based biopharmaceutical company focused on oncology drug development, announced on January 27 a strategic commercialization partnership with SteinCares, a leading pharmaceutical company in the Latin American market. Under the licensing and commercialization agreement, SteinCares will obtain the rights to commercialize sugemalimab in 10…
-
MicroPort’s Fireliums Receives NMPA Approval for Coronary Bifurcation Stenosis Treatment
•
Shanghai-based medical device giant MicroPort Scientific Corp. (HKG: 0853) has announced receiving marketing approval from the National Medical Products Administration (NMPA) for its coronary rapamycin drug balloon dilation catheter, Fireliums, for dilation treatment of primary coronary artery bifurcation stenosis. This approval marks a significant milestone in the commercialization of this…
